Difference between revisions of "Maprotiline-sertraline"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = sertraline | | to = sertraline | ||
| stop = | | stop = | ||
| − | + | {{stopMaprotiline}} | |
| − | |||
| − | |||
| − | |||
| start = | | start = | ||
* '''Day 7:''' simultaneously start administration of sertraline in a normal dosage of 50 mg/day. | * '''Day 7:''' simultaneously start administration of sertraline in a normal dosage of 50 mg/day. | ||
| Line 12: | Line 9: | ||
| info = | | info = | ||
* Sertraline is a weak inhibitor of CYP2D6, which metabolizes maprotiline. | * Sertraline is a weak inhibitor of CYP2D6, which metabolizes maprotiline. | ||
| − | |||
}} | }} | ||
Revision as of 13:54, 2 November 2015
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from maprotiline to sertraline.[1] [2]
Stop maprotiline - Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
- Day 1: reduce dosage of maprotiline to 50 mg/day.
- Day 7: reduce dosage of maprotiline to 25 mg/day.
- Day 14: stop dosage of maprotiline.
Start sertraline- Day 7: simultaneously start administration of sertraline in a normal dosage of 50 mg/day.
- Day 14: stop administration of maprotiline and continue administration of sertraline in a dosage of 50-100 mg/day.
More information- Sertraline is a weak inhibitor of CYP2D6, which metabolizes maprotiline.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
